Sitryx to participate in upcoming April investor conferences
Oxford, UK and Boston, MA – March 26, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that management will be participating in the following upcoming investor conferences:
Wells Fargo Spring Virtual Private Biopharma Symposium
Date: Wednesday, April 8, 2026
Format: Virtual
Needham & Company 25th Annual Healthcare Conference
Date: Monday, April 13 – Thursday, April 16, 2026
Format: Virtual
H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Date: Tuesday, April 14 – Wednesday, April 15, 2026
Format: Virtual
Piper Sandler Spring Biopharma Symposium
Date: Wednesday, April 15 – Thursday, April 16, 2026
Location: Boston, MA
Management will be in attendance to participate in one-on-one and group meetings during each event. Interested investors should contact their Wells Fargo, Needham & Company, H.C. Wainwright and Piper Sandler representatives, respectively, to schedule meetings.
Ends
For more information about Sitryx please contact:
ICR Healthcare
Mary-Jane Elliott, David Daley, Evi Useh
+44 (0)20 3709 5700
Sitryx@icrhealthcare.com
About Sitryx
Sitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases.
Established with seed funding from SV Health Investors, Sitryx has an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK.
Sitryx is headquartered in Oxford, UK with additional presence in Boston, MA. For more information, please visit www.sitryx.com.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
